22.626 articles found

Effects of GDNF pretreatment on function and survival of transplanted fetal ventral mesencephalic cells in the 6-OHDA rat model of Parkinson's disease.

Andereggen L, Meyer M, Guzman R, Ducray AD, Widmer HR.

Brain Res · 2009-04-21

DOI: 10.1016/j.brainres.2009.04.021PMID: 19389387

Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.

Song L, Kong M, Ma Y, Ba M, Liu Z.

Brain Res · 2009-04-21

DOI: 10.1016/j.brainres.2009.04.028PMID: 19393228

PROCESS FOR TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS, RHEUMATOID ARTHRITIS, TREMORS/PARKINSON'S DISEASE, MULTIPLE SCLEROSIS AND NON-VIRAL BASED CANCERS

NELSON GEORGE.

· 2009-04-20

Quality indicators for physiotherapy in Parkinson's disease.

Nijkrake MJ, Keus SH, Ewalds H, Overeem S, Braspenning JC, Oostendorp RA, Hendriks EJ, Bloem BR, Munneke M.

Eur J Phys Rehabil Med · 2009-04-20

DOI: 10.1016/s1353-8020(08)70913-1PMID: 19377415

Physical activity, eccentric contractions of plantar flexors, and neurogenesis: therapeutic potential of flat shoes in psychiatric and neurological disorders.

Flensmark J.

Med Hypotheses · 2009-04-11

DOI: 10.1016/j.mehy.2009.03.009PMID: 19364629

Prospects of stem cell therapy for replacing dopamine neurons in Parkinson's disease.

Lindvall O, Kokaia Z.

Trends Pharmacol Sci · 2009-04-09

DOI: 10.1016/j.tips.2009.03.001PMID: 19362379

Update on ropinirole in the treatment of Parkinson's disease.

Shill HA, Stacy M.

Neuropsychiatr Dis Treat · 2009-04-08

DOI: 10.2147/ndt.s3237PMID: 19557097

Postulated vasoactive neuropeptide immunopathology affecting the blood-brain/blood-spinal barrier in certain neuropsychiatric fatigue-related conditions: A role for phosphodiesterase inhibitors in treatment?

Staines DR, Brenu EW, Marshall-Gradisnik S.

Neuropsychiatr Dis Treat · 2009-04-08

DOI: 10.2147/ndt.s4176PMID: 19557103

Dopaminergic treatment is associated with decreased body weight in patients with Parkinson's disease and dyskinesias.

Bachmann CG, Zapf A, Brunner E, Trenkwalder C.

Eur J Neurol · 2009-04-03

DOI: 10.1111/j.1468-1331.2009.02617.xPMID: 19374662

Mitochondria as targets for chemotherapy.

Gogvadze V, Orrenius S, Zhivotovsky B.

Apoptosis · 2009-04-01

DOI: 10.1007/s10495-009-0323-0PMID: 19205885

A multimodal approach to physical therapy in Parkinson's disease: optimizing strategies.

Mestre T, Ferreira JJ, Jain S.

Mov Disord · 2009-04-01

DOI: 10.1002/mds.22478PMID: 19224597

Levodopa-related wearing-off in Parkinson's disease: identification and management.

Pahwa R, Lyons KE.

Curr Med Res Opin · 2009-04-01

DOI: 10.1185/03007990902779319PMID: 19228103